| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
Jyong Biotech Ltd.$2.43
+0.07 (+2.97%)
Market Cap
163.46 M
EPS
-0.06
P/E Ratio
-
Value Trade
112.91 K
2.87 %
Week
-2.27 %
1 Month
9.14 %
3 Month
-93.45 %
6 Month
-85.67 %
5 Year
-85.67 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
23.64 K
52 Week Range
1.43 - 67
% held by Insiders
62.2 %
% held by Institutions
0.61 %
Enterprise Value
180.83 M
Total Shares
75.99 M
Short %
0.77 %
Float Shares
31.08 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jyong Biotech Ltd.
7Total events
3Upcoming
4Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 2
TBD
T1NDA Submission
Subscribe to view catalyst details
TBD
T1Partnership / License
Subscribe to view catalyst details
Event history 2
TBD
●Oral PresentationBotresoFiledPresentation
Subscribe to view catalyst details
TBD
●Partnership / LicenseBotresoFiledCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Botreso® | BPH | Phase 3 | 2026-04-28 | no drug-related serious adverse events were observed | Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio Read More | |
Botreso® | BPH | Phase 3 | 2026-04-28 | no drug-related serious adverse events were observed | Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio Read More | |
Botreso® | BPH | Phase 3 | 2026-04-28 | no drug-related serious adverse events were observed | Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MENS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MENS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MENS▲ +3%today
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and...
Jyong Biotech Ltd. is focusing on global licensing partnerships to address the growing medical needs in the urology sector, specifically for Benign Prostatic Hyperplasia (BPH). The company has advanced its botanical drug candidate, Botreso®, to Phase III clinical trials and aims to meet the significant unmet medical needs in BPH treatments. The global BPH market is expected to grow substantially, highlighting the potential for Jyong Biotech's innovations.
Read more →MENSJyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
Jyong Biotech Ltd. is focusing on global licensing partnerships to address the growing needs in the urology sector, particularly for Benign Prostatic Hyperplasia (BPH). The company has made significant strides by advancing its botanical drug candidate, Botreso®, into Phase III clinical trials. With the BPH market expected to grow substantially, Jyong aims to provide safer treatment options while navigating the challenges of existing therapies.
Read more →MENS▲ +8.3%on this news
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
Jyong Biotech Ltd. participated in the BIO 2026 International Convention, showcasing its botanical drug candidate, Botreso® (API-1), aimed at treating benign prostatic hyperplasia and lower urinary tract symptoms. The company is advancing global licensing discussions and preparing for New Drug Application submissions. With a focus on safety and efficacy, Jyong Biotech aims to expand its market presence in the U.S., Europe, and Asia.
Read more →MENS▲ +8.3%on this newsshared move
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and...
Jyong Biotech Ltd. participated in the BIO 2026 International Convention, showcasing its botanical drug candidate Botreso® aimed at treating benign prostatic hyperplasia and lower urinary tract symptoms. The company is advancing its global licensing discussions and preparing for New Drug Application submissions. With a growing market for these conditions, Jyong Biotech aims to expedite commercialization through partnerships.
Read more →MENS▼ -6.4%on this news
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and...
Jyong Biotech's CEO, Fu-Feng Kuo, discussed the company's strategic vision in a PharmaBoardroom interview, emphasizing the FDA pathway for their lead asset, Botreso®. The company aims to address the market for benign prostatic hyperplasia (BPH) with innovative plant-derived therapeutics. Kuo highlighted the potential for transformative clinical outcomes and the importance of securing FDA approval to access global markets.
Read more →MENSJyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
Jyong Biotech's CEO, Fu-Feng Kuo, outlined the company's FDA pathway and global strategy in a PharmaBoardroom interview. The firm is advancing its lead botanical drug, Botreso®, aimed at treating benign prostatic hyperplasia (BPH), and is preparing for a New Drug Application submission. The company emphasizes its commitment to developing effective treatments with low side effects, while also exploring partnerships for its Prostate Cancer Prevention asset.
Read more →MENSJyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Jyong Biotech Ltd. has filed its annual report on Form 20-F for the fiscal year 2025 with the SEC. The report includes audited financial statements and is available on the company’s investor relations website. Jyong Biotech specializes in developing plant-derived therapeutics, particularly for urinary system diseases, and aims to meet health needs with innovative drugs.
Read more →MENSJyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
Jyong Biotech has advanced its market access strategies for its innovative botanical drugs, Botreso® and PCP, following successful clinical trials. Both products demonstrate significant safety and efficacy, particularly in addressing prostate health issues. The company aims to leverage its unique positioning and technological advantages to capture a growing market for BPH treatments.
Read more →MENSJyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and...
Jyong Biotech Ltd. has advanced its market access strategies for its innovative botanical drugs, Botreso® and PCP, following successful clinical trials. Botreso® has completed four Phase III trials, while PCP has finished its Phase II trial, both demonstrating significant safety and efficacy. The company aims to leverage its unique product positioning and technological advantages to capture a growing market in BPH treatment.
Read more →MENSJyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
Jyong Biotech has updated on its innovative drug MCS®-2, which is the first oral botanical new drug to complete Phase III trials for benign prostatic hyperplasia (BPH). The drug has shown excellent safety and is positioned to meet a significant market need for effective BPH treatments. Jyong Biotech emphasizes its commitment to innovation and regulatory compliance as it prepares for commercialization.
Read more →MENSJyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2 Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and...
Jyong Biotech has updated on its innovative drug MCS®-2, which is the first oral botanical new drug to complete Phase III trials for benign prostatic hyperplasia (BPH). The drug has shown excellent safety and efficacy across multiple trials in the U.S. and Taiwan. With a focus on addressing the unmet needs in BPH treatment, Jyong Biotech aims to capitalize on the growing market for prostate disease therapies. The company emphasizes its commitment to quality and regulatory compliance in drug development.
Read more →MENSJyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
Jyong Biotech has reported successful Phase II trial results for MCS-8, showing a 27.3% reduction in prostate cancer incidence among high-risk subjects. The trial also revealed significant metabolic benefits, including improved lipid profiles. The company is pursuing commercialization in Asia through strategic partnerships, positioning itself as a leader in preventative medicine.
Read more →MENSJyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and...
Jyong Biotech Ltd. has announced the successful completion of its Phase II trial for MCS-8, demonstrating a significant reduction in prostate cancer incidence among high-risk subjects. The trial also revealed potential metabolic benefits, including improved lipid profiles. The company is pursuing commercialization in Asia through strategic partnerships, positioning itself as a leader in preventative medicine.
Read more →MENS▼ -7.8%on this news· ran to -18% by day 3
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
Jyong Biotech's Phase II trial results for MCS-8 indicate promising efficacy in prostate cancer prevention and improved metabolic indicators. The study showed a 27.3% reduction in overall prostate cancer incidence and favorable trends in disease progression. The drug demonstrated a good safety profile with no serious adverse events, supporting its potential for long-term use.
Read more →MENSJYONG BIOTECH LIMITED UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (in thousand US Dollars, except share and per share data) As of
JYONG Biotech Limited released its unaudited interim condensed consolidated financial results for the six months ending June 30, 2025. The company reported an increase in net loss from $1,326k in 2024 to $1,252k. Additionally, there was a notable rise in total comprehensive loss, which increased from $853k to $2,411k. The shareholders' deficit also widened, reaching $22,472k as of June 30, 2025.
Read more →MENSJyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering New Taipei City, Taiwan
Jyong Biotech Ltd. has announced the pricing of its initial public offering (IPO) at $7.50 per share, aiming to raise approximately $20 million. The company focuses on developing plant-derived drugs for urinary system diseases and has secured approval for its shares to be listed on the Nasdaq under the ticker 'MENS'. Proceeds from the IPO will be allocated to various clinical trial phases, enhancing its pipeline of botanical drug candidates. The offering is expected to close soon, subject to customary conditions being met.
Read more →Competitive Position
How MENS ranks across every disease it competes inCompetitive Position is a premium feature
See how MENS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial